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ABSTRACT:  Opioids, like morphine, are the mainstay analgesics for the treatment and control of 
pain.  Despite this, they often exhibit severe side effects that limit dose; patients often become 
tolerant and dependent on these drugs, which remains a major health concern.  The analgesic 
actions of opioids are primarily mediated via the µ-opioid receptor, a member of the G protein-
coupled receptor superfamily. Thus far, development of small molecule fluorescent ligands for this 
receptor has resulted in antagonists, somewhat limiting the use of these probes.  Herein, we describe 
our work on the development of a small molecule fluorescent probe based on the clinically used 
opiate morphine, and initial characterization of its behavior in cell-based assays. 
  
¢   INTRODUCTION 
Opioids represent a useful class of drugs for the control and management of pain.  Morphine and 
codeine, the active ingredients in opium from the plant Papaver somniferum, have been used for 
this purpose since early history.1  More recently, semi-synthetic opioids have also become 
important therapeutic agents, with drugs such as oxycodone being useful therapeutic agents.  Semi-
synthetic opioid antagonists such as naloxone and naltrexone are also important therapeutic agents 
to treat opioid overdose.  Despite their clinical effectiveness, opioid agonists suffer from significant 
drawbacks; dose-limiting side effects such as constipation, sedation and respiratory depression are 
common.1  In addition to this, opioid drugs tend to be addictive and require higher doses as the 
patient develops a tolerance for them, further compounding the problem.  In the United States alone, 
the CDC reported that opioid related deaths accounted for 61% of drug overdose related deaths 
between 2010 to 2015.2  Furthermore, the number of incidents has increased dramatically, with 
death rates tripling during this period compared to 1999. 
 Opioids act via the three opioid receptor subtypes, namely the µ, κ and δ opioid receptors 
(MOR, KOR, and DOR respectively).  The more recently discovered nociception/orphanin FQ 
peptide receptor (NOPr) is another member of the opioid receptor family, but does not bind these 
clinically used morphinan opioids.3  Herein, we will only discuss the MOR, as this receptor is the 
primary target of the most commonly used analgesics,4 and therefore holds significant clinical 
interest for the development of future analgesics. 
 Binding of an agonist to MOR typically activates Gi/o proteins, resulting in inhibition of 
adenylate cyclase, and therefore a reduction in cyclic adenosine monophosphate (cAMP) levels.1  
This results in an influx of K+ via G protein-mediated K+ channels, causing neuron 
hyperpolarization and blockade of voltage-gated Ca2+ channels.5  Hyperpolarization reduces firing 
potential, and therefore blockade of pain signaling, giving opioids their analgesic effects.  Upon 
prolonged activation, β-arrestin 2 recruitment to the MOR terminates signaling and induces 
internalization of the receptor. 
 However, not all opioids recruit arrestin and internalize with the same efficacy and, indeed, β-
arrestin biased ligands have been discovered which give different pharmacological outcomes.6  The 
prototypical opiate morphine causes very little β-arrestin 2 recruitment following MOR receptor 
activation, while also inducing significant dependency and tolerance in the patient.7  Herkinorin, 
like morphine, also provides analgesia with little β-arrestin 2 recruitment, but shows very low 
dependence and tolerance liabilities in animal models.8  DAMGO, a peptidic agonist, induces β-
arrestin 2 recruitment while having reduced dependence and tolerance liabilities.7  PZM21, a more 
recent example, appears to be biased towards Gi signaling, lacking any significant β-arrestin 2 
recruitment.6  Analgesia in mice has been demonstrated with fewer side effects compared to 
morphine.  Just from these few examples, it can be seen that different agonists have different 
pharmacological outcomes despite all acting at MOR.  Furthermore, Bohn et al. have demonstrated 
that tolerance and dependence are not necessarily correlated, as β-arrestin 2 knockout mice still 
develop a dependence towards morphine, but lack the expected tolerance.9 
 Understanding the mechanisms behind the different abilities of opioid ligands to promote 
arrestin recruitment and regulate receptor signaling poses a significant challenge.  The development 
of fluorescent ligands to visualize G protein-coupled receptors (GPCRs) in live cells represents a 
major advantage that circumvents the use of recombinant cells and allows the study of these 
receptors in natively expressing systems.  One of the earliest examples of a fluorescent opioid is 
described by Fournie-Zaluski et al. in which enkephalins were conjugated to a fluorescent dansyl 
sulfonyl group.10  This particular ligand has seen limited use, perhaps due to the UV excitation 
maximum and poor quantum yield of the dansyl sulfonyl group not being particularly suitable to 
modern live cell imaging techniques.  The same was true of probes described by Mihara et al. who 
conjugated enkephalins to the fluorophore L-1-pyrenylalanine.11  In both cases, introduction of the 
fluorescent moiety resulted in a reduction in binding affinity compared to the native ligand.  More 
recent variants of these peptidic conjugates have been described by Arttamangkul et al. using more 
modern fluorophores.12  These new fluorescent ligands have been used to study MOR 
internalization, desensitization and recycling.13–15 
 Small molecule fluorescent opioids have also been described.  Kolb et al. described the 
synthesis of several fluorescent antagonists based on naloxone and naltrexone.16  Another opioid 
probe bearing 7-nitrobenzo-2-oxa-1,3-diazole fluorescent label was described by Archer et al.17 
quickly followed by another example from Emmerson et al.18  Most recently, Schembri et al. 
synthesized a series of orvinols based on the buprenorphine scaffold and conjugated them to a range 
of fluorophores.19  However, in all these cases, the fluorescent probes described were antagonists.  
Although fluorescent antagonists are still useful to visualize receptors at the plasma membrane and 
to assess receptor binding, by definition, they do not allow the study of events that follow receptor 
activation.  Herein, we describe our work on the synthesis and evaluation of small molecule 
fluorescent opioid partial agonists. 
  
¢   RESULTS 
Model Morphine Congeners.  Our aim was to develop fluorescent derivatives of morphine, as this 
clinically used drug is of particular interest.  The C-6 position was chosen as our linking point, as 
the body of prior literature suggests that modifications at this point have minimal effect on ligand 
activity compared to alternative positions.20,21  In order to assess whether our linking modifications 
would affect ligand activity, we first assessed the proposed structural modifications.  To this end, 
we designed and synthesized model compounds comprising the targeting ligand with short chain 
linker modifications.  Several linking methods were proposed and these model compounds are 
illustrated in Figure 1.  Importantly, these compounds and their syntheses were designed such that 




Figure 1.  Pre-congeners synthesized for assessing linker suitability.  Note preservation of the C-6 
stereocenter. 
 
 Synthesis of our model compounds employed morphine as the starting material.  This 
approach necessitated initial protection of the C-3 phenol, for which we chose the para-
methoxybenzyl (PMB) group, and this was installed in modest yield to afford 6 (Scheme 1).  This 



































 Scheme 1.  Synthesis of C-6 position amine. 
 
Reagents and conditions: (a) 3 M KOH in MeOH, PMB-Cl, DMF, RT, 4 h, 46%; (b) (i) benzoic 
acid, PPh3, DIAD, toluene, 0 oC to RT, 4 h; (ii) 1:1 EtOH/1 M KOH, reflux, 20 min, 78%; (c) (i) 
phthalimide, PPh3, DIAD, toluene, 0 oC to RT, 4 h; (ii) EtOH, N2H4.H2O, reflux, 1 h, 34%. 
 
 
 An amine moiety was subsequently introduced into the 6-position to provide a point of 
attachment which retains the capacity to act as a hydrogen bond donor as per the 6-OH of morphine 
after the linker has been attached.  As we also wished to maintain the native stereochemistry of the 
C-6 position a double Mitsunobu approach was employed to install this amine, noting that the 
Mitsunobu reaction has previously been reported to invert this stereocenter in closely related 
opiates.22-25  Accordingly, 6-OH was first inverted using benzoic acid under Mitsunobu conditions 
followed by saponification of the resultant ester to give the 6-isomorphine derivative 7.  A 
comparison of the NMR spectra of compounds 6 and 7 (Figure S1) demonstrated stereospecific 
inversion of this chiral center.  Compound 7 was subsequently converted to the desired S-
stereoisomer via a phthalimide promoted Mitsunobu reaction.  Treatment of the phthalimide group 
with hydrazine hydrate afforded 8, allowing for linking and elongation to the desired model 






















 Scheme 2.  Synthesis of C-6 position ester and amide pre-congeners. 
 
 
Reagents and conditions: (a) Hexanoyl chloride, pyridine, 70 oC, 18 h, 49-80%; (b) triethylsilane, 
TFA, DCM, RT, 20 min, 16-39%; (c) succinic anhydride, DMAP, TEA, MeCN, 65 oC, 16 h, 28-
77%; (d) EDC.HCl, HOBt, TEA, methylamine (2 M in THF), MeCN or DMF, RT, 3 h, 63-84%. 
 
 
 Two different approaches for ester and amide conjugation were trialed.  The first, using an 
acid chloride, yielded compounds 1 and 3 following phenolic deprotection (Scheme 2).  
Fluorophore conjugation via acyl chloride chemistry is not a viable synthetic strategy and we 
therefore designed a method which would facilitate milder reaction conditions.  Ring opening of 
succinic anhydride via the C-6 amine or alcohol provided a convenient handle for further elongation 
and subsequent fluorophore conjugation under milder conditions.  Methylamine capping of this 
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 Scheme 3.  Synthesis of C-6 position ether pre-congener. 
 
Reagents and conditions: (a) (i) NaH, tert-butyl bromoacetate, THF, 0oC-RT, 1 h; (ii) triethylsilane, 
TFA, DCM, RT, 1 h, 58%; (b) HCTU, TEA, propylamine, DMF, RT, 19 h  ¸17%. 
 
 
 As an alternative linking method, an ether linker was also proposed.  Using tert-butyl 
bromoacetate to give the C-6 ether, followed by global deprotection gave 15, again possessing a 
convenient handle for further linker elongation.  This handle was capped with propylamine to 
provide the final model amide 5 (Scheme 3). 
 Model compounds were functionally assessed and compared to morphine using a 
bioluminescence resonance energy transfer (BRET)-based cAMP sensor using YFP-Epac-RLuc 
assay (CAMYEL) in HEK293 cells expressing the human MOR (hMOR) and normalized against 
forskolin (Table 1).  All compounds were less potent than morphine, however the ester linked 
model compounds (1 and 2) maintained potencies in the mid nM range, while the amide-linked 
model compounds (3 and 4) showed a significant loss in potency beyond the µM range.  The ether 
linked model compound 5 however maintained the same level of maximum activity and was the 























 Table 1.  pEC50 of model compounds as assessed in a cAMP CAMYEL BRET assay against 
hMOR.  
 
Cpd 6-Substituent pEC50 ± SEM a Relative  
potency b 
Emax ± SEM a,c Relative 
efficacy d 
Morphine -OH 7.07 ± 0.13 - 35.7 ± 1.7 - 
1 
 
6.46 ± 0.11 0.24 37.1 ± 1.9 1.04 
2 
 
6.45 ± 0.11 0.24 28.6 ±1.4 0.80 
3 
 
5.98 ± 0.11 0.08 28.9 ± 1.9 0.81 
4 
 
5.35 ± 0.71 0.02 23.3 ± 11.7 0.65 
5 
 
6.81 ± 0.14 0.55 37.5 ± 2.4 1.05 
a Results presented are the average of 3 independent experiments. 
b Relative to morphine. Relative potency was calculated by dividing EC50(morphine) by 
EC50(compound).  
c Emax is the % inhibition of Forskolin-induced cAMP. 
d Relative to morphine. Relative efficacy was calculated by dividing Emax(compound) by 
Emax(morphine). 
 
Morphine-Cy5 Conjugates.  We then proceeded to synthesize two fluorescent probes based on 
linker designs 2 and 5.  Sulfo-Cy5 was chosen as the fluorescent tag, as previous work by Schembri 
et al. suggested that this particular fluorophore had the least potential for inducing non-specific 
binding to the cell membrane.19  The functional handles on 11 and 15 were elongated with a simple 
Boc-protected diamine chain, followed by global deprotection and chemoselective conjugation to 
sulfo-Cy5 to give the final fluorescent morphine probes 18 and 21 (Schemes 4 and 5, respectively).  
In the case of 18, the coupling reaction with sulfo-Cy5 NHS ester failed to proceed to completion 
after 7 hours.  As it was thought this may have resulted from the hydrolysis of the NHS ester to the 
corresponding carboxylic acid, HCTU was added to drive the reaction to completion (Scheme 4).  
In the case of 21, sulfo-Cy5 free acid was used in place of the NHS ester and was installed under 
standard HCTU coupling conditions (Scheme 5). 
 
 
Scheme 4.  Synthesis of ester linked morphine-Cy5 probe 18. 
 
 
Reagents and conditions: (a) N-Boc-diaminoethane, HCTU, TEA, DMF, RT, 19 h, 83%; (b) 
triethylsilane, TFA, DCM, RT, 1 h, 51%; (c) Sulfo-Cy5 NHS ester (Lumiprobe®), HCTU, TEA, 








































16    R1 = PMB, R2 = Boc
18
17    R1 = R2 = H
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 Scheme 5.  Synthesis of ether linked morphine-Cy5 probe 21. 
 
Reagents and conditions: (a) N-Boc-diaminobutane, EDC.HCl, HOBt, TEA, DMF, RT, 17 h, 36%; 
(b) TFA, CHCl3, RT, 1 h, quantitative; (c) Sulfo-Cy5, HCTU, TEA, DMF, RT, 18 h, 40%. 
 
 
 Functional assessment of 18 and 21 was conducted in the same manner as the model 
conjugates (Table 2).  Although both sulfo-Cy5 derivatives were still able to activate MOR with 
potencies in the nM range, they showed a significant loss of efficacy (Emax).  This loss in activity is 
consistent with previous literature compounds, where attachment of a fluorescent tag typically 
results in decreased activity.12,26  A comparison with DAMGO in the same assay revealed that 21 
clearly behaves as a partial agonist, albeit with a lower efficacy compared to the parent compound 
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 Table 2.  pEC50 assessment of morphine-Cy5 probes. 
 
Probe pEC50 ± SEM a Relative 
potency b 
Emax ± SEM a,c Relative 
efficacy d 
Morphine 7.07 ± 0.13 -- 35.7 ± 1.7 -- 
18 7.34 ± 0.37 1.85 10.7 ± 1.2 0.30 
21 6.30 ± 0.44 0.17 15.0 ± 3.2 0.42 
a Results presented are the average of 3 independent experiments. 
b Relative to morphine.  Relative potency was calculated by dividing EC50(morphine) by 
EC50(compound).  
c Emax is the % inhibition of Forskolin-induced cAMP. 







Figure 2. CAMYEL assay comparing DAMGO, morphine and 21.  The probe compound 21 is 
clearly a partial agonist compared to the full agonist DAMGO.  Morphine is known to be a partial 
agonist, but may give differing levels of efficacy depending on the assay used.  Results for 
DAMGO and morphine are consistent with those previously reported.27,28  Results presented are an 
average of 3 independent experiments, with error bars representing SEM. 
 



























 We then assessed whether compounds 18 and 21 were suitable for receptor visualization using 
confocal microscopy.  Initial experiments were conducted to determine whether 18 and 21 bound 
specifically to the MOR.  HEK293 stably expressing SNAP-tagged hMOR (SNAP-hMOR) were 
pre-incubated with cell impermeable SNAP-Surface® 488 (BG-488, New England BioLabs®, 
Figure 3) to label the cell surface SNAP-hMOR, then incubated in the presence or absence of the 
antagonist naloxone and before exposure to the fluorescent probes.  Despite having a higher 
apparent pEC50 value, 18 showed no specific binding to the cell surface receptor population (Figure 
4, panel A).  On the other hand, 21 was observed to localize at the surface of cells expressing 
SNAP-hMOR (Figure 4, panel B).  21 binding was abolished by pre-incubation with naloxone 





Figure 3.  SNAP-Surface® 488 (New England BioLabs®), a cell impermeable dye targeted to the 


















 Figure 4.  Initial high-content imaging of probes with HEK293 cells expressing SNAP-hMOR.  
Images are representative of 3 independent experiments.  A) 18 at 3 µM, no specific binding of the 
probe to the cell surface was observed; B) 21 at 1 µM, binding of the probe to the cell surface was 
observed; C) 21 at 1 µM pre-incubated with naloxone (1 µM, 30 min, 37oC), complete blockade of 
probe binding was observed.  Scale bars 50 µm. 
  
Having demonstrated that 21 could be used to visualize specific binding to the MOR on 
HEK293 cell membranes, this probe was selected for subsequent study.  In HEK293 cells stably 
expressing SNAP-hMOR and pre-incubated with BG-488, it was found that 21 co-localized with 
SNAP-hMOR predominantly on the cell membrane (Figure 5, panels A - B), which was prevented 
by pre-incubation with naloxone, confirming the membrane binding of 21 was to the hMOR (Figure 
5, panel C).  The bulk of the co-localized fluorescence remained at the cell surface.  Although some 
co-localized signals within the cells were present, the signal from intracellular compartments was 
very weak compared to that at the plasma membrane.  These data are in keeping with literature data, 
which suggests that morphine only poorly induces internalization of the receptor-ligand complex.7  
Since incubation with BG-488 only labels cell surface populations of SNAP-hMOR, any 
internalized receptor population must therefore have previously been on the cell surface.  In keeping 
with prior literature, it was found that a wash step removed bound ligand (Figure 5, panel D).19    
This is consistent with the fast koff rate of non-peptide opioids and the known fast koff rate of 
morphine, so this behavior is not unexpected. In any case, a wash step is typically not included in 
confocal microscopy experiments, particularly where there is no significant background from 




Figure 5.  Live cell confocal imaging of 21 in cells expressing SNAP-hMOR.  Images are 
representative of 3 independent experiments.  In all cases, 21 was incubated at 500 nM for 30 min at 
37oC following pre-treatment (with or without naloxone). A, B) Typical results obtained from 
confocal microscopy, the white arrows indicate areas where co-localization of intracellular receptor 
populations with the fluorescent ligand were observed; C) 21 following pre-incubation with 
naloxone (1 µM, 30 min, 37oC), indicating specific binding of the probe to hMOR; D) Loss of 
ligand signal following a post-incubation wash.  This is typical of non-peptide opioids, which tend 
to have a fast koff rate.  Scale bars 20 µm. 
 
 
In the previous experiments, the EC50 concentration of 500 nM was used, thus we wanted to 
assess the behavior of 21 above this concentration.  The use of 10 µM of 21 necessitated a wash 
step to remove background fluorescence from any excess ligand (Figure 6, panel A). As 
demonstrated, the level of observed co-localization between 21 and SNAP-hMOR in the 
intracellular compartment is significantly increased, with minimal cell surface co-localization due to 
the wash step as expected.  Furthermore, this signal could be removed by blockade with naloxone, 
further demonstrating the lack of non-specific binding of 21 even at this higher concentration 
(Figure 6, panel B).  
 
 
Figure 6.  Live cell confocal imaging of 21 at increased concentration in cells expressing SNAP-
hMOR.  Images are representative of 3 independent experiments.  A) 21 at 10 µM, note the 
increased level of internalized receptor populations compared to the data presented in Figure 4; B) 
21 at 10 µM following pre-incubation with naloxone (1 µM, 30 min, 37 oC), demonstrating specific 
displacement of 21 with little background fluorescence.  Scale bars 20 µm. 
 
To directly compare, experiments were conducted using the parent compound morphine as the 
ligand (Figure 7).  Obviously the lack of a fluorescent tag prevents direct visualization of the ligand, 
but observation of the tagged receptor fluorescence is still of value, as it enables visual comparisons 
to be made between the behavior of our fluorescently tagged probe and its parent compound.  A 
baseline level of receptor internalization was first determined in cells with no ligand present (Figure 
7, panel A).  These data show that a low constitutive level of receptor internalization is present, 
even without stimulation.  Morphine at 500 nM does not induce any significant receptor 
internalization, with levels similar to that of the baseline level (Figure 7, Panel B).  Furthermore, 
these levels of internalization are similar to when 500 nM of 21 was used (Figure 5, Panel A, B).  
This reinforces the idea that morphine is only weakly able to induce internalization of the MOR.  
Furthermore, at 10 µM morphine, the level of internalization was comparable to that observed with 
10 µM of 21 (Figure 7, Panel C compared to Figure 6, Panel A).  Taken together, these data suggest 






Figure 7.  Live cell confocal imaging of SNAP-hMOR in cells exposed to morphine for comparison 
to 21.  Images are representative of 3 independent experiments.  A) Cells with no stimulation, note 
the constitutive receptor turnover, even in the absence of any external internalizing stimuli; B) 500 
nM morphine, the level of internalization is similar to that observed when no stimuli is applied, 
which is in keeping with literature data suggesting morphine’s inability to induce internalization; C) 
10 µM morphine, significantly more receptor populations are observed to internalize, and therefore 
can be attributed to the ligand stimulus.  Scale bars 20 µm. 
 
  
¢   DISCUSSION AND CONCLUSIONS 
Herein, we have described the design and synthesis of a fluorescent partial agonist probe for 
MOR based on the commonly used analgesic morphine.  Our studies have shown that probe 
compound 21 is able to bind to hMOR on cell membranes, and behaves in a similar manner to the 
parent compound morphine.  At EC50 concentrations, the probe does not induce internalization of 
the receptor, but is present in intracellular compartments at levels consistent with constitutive 
turnover. At higher concentrations, the probe is able to induce internalization at similar levels to 
morphine.  These data suggest that the probe compound 21 may be a used as a tool compound to 
simulate the behavior of morphine, much in the same way DERM-A594 is used as a tool compound 
for the study of endogenous opioid peptides.15  It is clear that morphine has significantly different 
signaling profile compared to peptides,23,24  and therefore small molecule-based fluorescent probes 
may lead to different outcomes compared to studies where fluorescent peptides have been utilized.  
This new tool compound could also be used in conjunction with the previously described small-
molecule fluorescent opioid antagonists to study the differences in ligand-receptor complexes in 
natively expressing systems, rather than in transfected systems.19 
 
¢   EXPERIMENTAL SECTION 
Chemistry.  Chemicals and solvents were purchased from standard suppliers and used 
without further purification.  Davisil® silica gel (40-63 µm) for flash column chromatography was 
supplied by Grace Davison Discovery Sciences (Victoria, Australia) and deuterated solvents were 
purchased from Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem PTY. Ltd, 
Victoria, Australia).  Davisil® reverse phase silica gel (C18, 10–14 µm) for reverse phase flash 
column chromatography was supplied by Grace Davison Discovery Sciences (Victoria, Australia) 
and run using the following buffers; buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in MeCN. 
Reactions were monitored by thin layer chromatography on commercially available pre-
coated aluminium-backed plates (Merck Kieselgel 60 F254).  Visualization was done by examination 
under UV light (254 and 366 nm).  General staining was carried out with KMnO4 or 
phosphomolybdic acid.  Organic solvents were evaporated in vacuo at ³ 40 °C (water bath 
temperature).  Purification using preparative layer chromatography (PLC) was carried out on 
Analtech preparative TLC plates (200 mm × 200 mm × 2 mm). 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance Nanobay III 400 MHz 
Ultrashield Plus spectrometer at 400.13 MHz and 100.62 MHz respectively.  Chemical shifts (δ) are 
recorded in parts per million (ppm) with reference to the chemical shift of the deuterated solvent.  
Coupling constants (J) are recorded in Hz and the significant multiplicities described by singlet (s), 
doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), doublet of 
triplets (dt). 
LC-MS were run to verify reaction outcome and purity using an Agilent 6120 Series Single 
Quad coupled to an Agilent 1260 Series HPLC.  The following buffers were used; buffer A: 0.1% 
formic acid in H2O; buffer B: 0.1% formic acid in MeCN.  The following gradient was used with a 
Poroshell 120 EC-C18 50 × 3.0 mm 2.7 micron column, and a flow rate of 0.5 mL/min and total run 
time of 5 min; 0–1 min 95% buffer A and 5% buffer B, from 1-2.5 min up to 0% buffer A and 
100% buffer B, held at this composition until 3.8 min, 3.8–4 min 95% buffer A and 5% buffer B, 
held until 5 min at this composition.  Mass spectra were acquired in positive and negative ion mode 
with a scan range of 100 – 1000 m/z.  UV detection was carried out at 214 and 254 nm.  
Preparative HPLC was performed using an Agilent 1260 infinity coupled with a binary 
preparative pump and Agilent 1260 FC-PS fraction collector, using Agilent OpenLAB CDS 
software (Rev C.01.04), and an Altima 5 µM C8 22 × 250 mm column.  The following buffers were 
used; buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in MeCN, with sample being run at a 
gradient of 5% buffer B to 100% buffer B over 15 min, at a flow rate of 15 mL/min.  All screening 
compounds were of > 95% purity. 
High resolution mass spectrometry – time of flight (HRMS TOF) was conducted using an 
Agilent 6224 TOF LC-MS mass spectrometer coupled to an Agilent 1290 Infinity.  
Chromatographic separation was performed using an Agilent Zorbax SB-C18 Rapid Resolution HT 
2.1 × 50 mm, 1.8 µm column using a gradient of 5 – 100% buffer B in buffer A over 3.5 min at 0.5 
mL/min; where buffers are as defined for LC-MS.  All mass data was acquired and reference mass 
corrected via a dual-spray ESI source.  Mass spectra were created by averaging scans across each 
peak and background subtracting against the first 10 seconds of the total ion count.  Acquisition was 
performed using the Agilent Mass Hunter Data Acquisition software, and analysis performed using 
Mass Hunter Qualitative Analysis software.  The mass spectrometer was run using the following 
conditions: drying gas flow 11 L/min, nebulizer 45 PSI, drying gas temperature 325 oC, capillary 
voltage 4000 V, fragmentor 160 V, skimmer 65 V, OCT RFV 750 V, scan range acquired 100 – 
1500 m/z, internal reference ions positive ion mode = m/z = 121.050873 & 922.009798. 
General Deprotection Procedure A.  The protected compound was dissolved in dry DCM 
(typically 5 mL) under an N2 atmosphere.  Triethylsilane (15 eq.) and TFA (20 eq.) were added to 
the reaction and the vessel purged with N2.  The reaction was allowed to stir for 30 - 60 min, then 
reduced in vacuo.  The resulting residue could then be purified via chromatography. 
6-O-Hexanoylmorphine (1).  Compound 9 (67 mg, 0.13 mmol, 1 eq.) was deprotected using 
general deprotection procedure A.  The resulting oil was purified by flash column chromatography 
(94:5:1 CHCl3/MeOH/TEA), and the resulting yellow oil was further purified by prep-HPLC to 
give the product as a solid white TFA salt (12 mg, 17%).  1H NMR (DMSO-d6) δ 10.04 (s, 1H), 
9.17 (s, 1H), 6.58 (d, J = 8.1 Hz, 1H), 6.50 (d, J = 8.1 Hz, 1H), 5.71–5.59 (m, 1H), 5.52–5.39 (m, J 
= 22.7, 9.8 Hz, 1H), 5.26–5.14 (m, 1H), 5.12–5.00 (m, J = 20.5, 6.6 Hz, 1H), 4.13 (s, 1H), 3.31 (d, J 
= 9.0 Hz, 1H), 3.19 (d, J = 19.7 Hz, 1H), 3.06 (d, J = 4.5 Hz, 1H), 2.98 (s, 1H), 2.92–2.78 (m, J = 
41.2 Hz, 3H), 2.71 (dd, J = 20.0, 6.7 Hz, 1H), 2.44–2.29 (m, 2H), 2.21 (td, J = 13.5, 4.6 Hz, 1H), 
1.98–1.70 (m, J = 46.3, 12.5 Hz, 1H), 1.64–1.51 (m, 2H), 1.34–1.21 (m, 4H), 0.87 (t, J = 6.9 Hz, 
3H); ESI-TOF HRMS m/z [M+H]+ C23H29NO4+ calc. 384.2169, found 384.2174. 
6-O-(4-Methylamino-4-oxobutanoyl)morphine (2).  Compound 13 (26 mg, 0.050 mmol, 1 
eq.) was deprotected using general deprotection procedure A.  The resulting oil was purified by 
prep-HPLC to give the product as a solid white TFA salt (4 mg, 16%).  1H NMR (DMSO-d6) δ 
10.04 (s, 1H), 9.23 (s, 1H), 7.85 (d, J = 4.4 Hz, 1H), 6.61–6.56 (m, J = 8.0, 3.1 Hz, 1H), 6.54–6.48 
(m, J = 8.1, 4.7 Hz, 1H), 5.65 (d, J = 10.0 Hz, 1H), 5.52–5.39 (m, J = 24.1, 10.0 Hz, 1H), 5.24–5.14 
(m, 1H), 5.09–4.99 (m, J = 22.2, 6.7 Hz, 1H), 4.13 (s, 1H), 3.34–3.25 (m, J = 8.5 Hz, 1H), 3.23–
3.13 (m, J = 19.7 Hz, 1H), 3.06 (d, J = 4.8 Hz, 1H), 2.98 (s, 1H), 2.89 (d, J = 3.1 Hz, 2H), 2.82–
2.67 (m, 2H), 2.62–2.58 (m, J = 6.9, 4.1 Hz, 2H), 2.57–2.55 (m, J = 4.5 Hz, 3H), 2.40 (t, J = 6.9 Hz, 
2H), 2.21 (td, J = 13.4, 4.4 Hz, 1H), 1.94–1.74 (m, J = 46.2, 11.8 Hz, 1H); ESI-TOF HRMS m/z 
[M+H]+ C22H27N2O5+ calc. 399.1914, found 399.1922. 
N-((4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7-yl)hexanamide (3).  Compound 10 (39 mg, 0.10 mmol, 1 
eq.) was deprotected using general deprotection procedure A.  The resulting oil was purified by 
prep-HPLC to give the product as a solid white TFA salt (12 mg, 31%).		[𝛼]%&' -21.4 (c 1.21 mg/mL, 
MeOH); 1H NMR (DMSO-d6) δ 10.11–9.88 (m, 1H), 9.28 (s, 1H), 8.20–8.05 (m, J = 25.3, 8.5 Hz, 
1H), 5.73 (dt, J = 10.3, 3.1 Hz, 1H), 5.58 (d, J = 10.5 Hz, 1H), 5.16–5.02 (m, J = 25.4 Hz, 1H), 3.85 
(t, J = 8.7 Hz, 1H), 3.74 (s, 1H), 3.27–3.20 (m, J = 7.0 Hz, 1H), 3.18 (s, 1H), 3.12–3.02 (m, J = 
19.8, 6.3 Hz, 1H), 2.98 (s, 1H), 2.89 (s, 3H), 2.77–2.56 (m, J = 48.6, 9.6 Hz, 2H), 2.40 (d, J = 8.1 
Hz, 1H), 2.17–1.97 (m, 3H), 1.87 (d, J = 11.8 Hz, 1H), 1.56–1.43 (m, 2H), 1.31–1.14 (m, 4H), 0.85 
(t, J = 7.0 Hz, 3H); ESI-TOF HRMS m/z [M+H]+ C23H31N2O3+ calc. 383.2329, found 383.2324. 
N1-((4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7-yl)-N4-methylsuccinamide (4).  Compound 14 (19 mg, 
0.037 mmol, 1 eq.) was deprotected using general deprotection procedure A.  The resulting oil was 
purified by prep-HPLC to give the product as a solid white TFA salt (7 mg, 39%).		[𝛼]%&' -21.9 (c 
0.78 mg/mL, MeOH); 1H NMR (DMSO-d6) δ 10.08–9.73 (m, J = 44.4 Hz, 1H), 9.25 (s, 1H), 8.28–
8.06 (m, J = 29.6, 9.0 Hz, 1H), 7.79 (d, J = 4.6 Hz, 1H), 5.78–5.68 (m, 1H), 5.65–5.57 (m, 1H), 
5.10 (t, J = 13.6 Hz, 1H), 3.94 (d, J = 4.6 Hz, 1H), 3.86 (t, J = 8.5 Hz, 1H), 3.22 (s, 1H), 3.17 (d, J = 
19.5 Hz, 1H), 3.10–2.96 (m, 2H), 2.89 (d, J = 4.6 Hz, 2H), 2.79–2.65 (m, 1H), 2.55 (d, J = 4.6 Hz, 
3H), 2.43–2.21 (m, 5H), 2.11–1.97 (m, 1H), 1.92–1.67 (m, 1H); ESI-TOF HRMS m/z [M+H]+ 
C22H28N3O4+ calc. 398.2074, found 398.2079. 
6-O-(2-oxo-2-(propylamino)ethyl)morphine (5).  Compound 15 (54 mg, 0.12 mmol, 1 eq.), 
HCTU (59 mg, 0.14 mmol, 1.2 eq.) and TEA (50 µL, 0.36 mmol, 3 eq.) were dissolved in dry DMF 
(800 µL) under an N2 atmosphere and allowed to stir at room temperature for 30 min.  A solution of 
propylamine (12 µL, 0.14 mmol, 1.2 eq.) in DMF (200 µL) was then added and the resulting 
solution allowed to stir at room temperature for 19 h.  The solvent was then removed in vacuo and 
the residue taken up in buffer B and again reduced in vacuo.  The residue was purified by flash 
column chromatography (74:25:1 MeOH/CHCl3/NH4OH), the solvent removed in vacuo and 
purified again by prep-HPLC to give the product as a solid white TFA salt (10 mg, 17%).		[𝛼]%&' -
106.1 (c 1.14 mg/mL, MeOH);  1H NMR (DMSO-d6) δ 9.81 (s, 1H), 9.18 (s, 1H), 7.74 (t, J = 5.7 
Hz, 1H), 6.62–6.52 (m, 1H), 6.52–6.43 (m, 1H), 5.82 (d, J = 9.7 Hz, 1H), 5.41–5.24 (m, 1H), 5.18–
5.02 (m, 1H), 4.16–3.97 (m, 4H), 3.29 (s, 1H), 3.20 (d, J = 19.8 Hz, 2H), 3.14–3.04 (m, 3H), 2.97 
(s, 1H), 2.90 (d, J = 3.9 Hz, 3H), 2.83 (d, J = 16.0 Hz, 2H), 2.74 (dd, J = 19.8, 6.6 Hz, 1H), 2.18 (td, 
J = 13.8, 4.9 Hz, 1H), 2.03–1.79 (m, 1H), 1.45 (h, J = 7.3 Hz, 2H), 0.84 (t, J = 7.4 Hz, 3H); ESI-
TOF HRMS m/z [M+H]+ C22H29N2O4+ calc. 385.2122, found 385.2130. 
3-O-(4-Methoxybenzyl)morphine (6).  Morphine (394 mg, 1.4 mmol, 1 eq.) was dissolved 
in DMF (1 mL) and KOH (3 M in MeOH, 552 µL, 1.7 mmol, 1.2 eq.) was added.  The resulting 
mixture was stirred for 10 min, then para-methoxybenzylchloride (215 µL, 1.6 mmol, 1.15 eq.) was 
added dropwise.  After stirring for 4 h at room temperature, aqueous citric acid (1 M, 10 mL) was 
added.  The resulting solution was washed successively with EtOAc (3 × 10 mL) and aqueous 
NH4OH (28%, 10 mL) was added to the aqueous phase.  The resulting turbid solution was extracted 
with 3:1 CHCl3/iPrOH (5 × 10 mL).  The combined organic layers were backwashed with brine, 
dried over Na2SO4 and the solvent removed in vacuo.  The resulting yellow oil was purified by flash 
column chromatography (98:1:1 DCM/MeOH/TEA).  The resulting clear oil was redissolved in 
EtOAc and evaporated again to give the product as a white solid (259 mg, 46%).  1H NMR (CDCl3) 
δ 7.33 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.53 (d, J = 8.1 Hz, 
1H), 5.67 (d, J = 9.7 Hz, 1H), 5.27 (d, J = 9.7 Hz, 1H), 5.04 (dd, J = 28.7, 11.4 Hz, 1H), 4.87 (d, J = 
6.3 Hz, 1H), 4.15 (d, J = 2.5 Hz, 1H), 3.80 (s, 2H), 3.36 (d, J = 2.4 Hz, 1H), 3.03 (d, J = 18.7 Hz, 
1H), 2.86 (s, 1H), 2.69 (s, 1H), 2.61 (dd, J = 11.8, 3.9 Hz, 1H), 2.44 (s, 1H), 2.39 (dd, J = 12.2, 3.1 
Hz, 1H), 2.30 (dd, J = 18.6, 6.0 Hz, 1H), 2.08 (td, J = 12.4, 4.8 Hz, 1H), 1.87 (d, J = 11.7 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 159.5, 147.1, 141.3, 133.6, 131.3, 129.5, 129.4, 128.2, 127.7, 119.7, 
116.0, 114.0, 91.3, 71.7, 66.5, 59.0, 55.4, 46.6, 43.1, 42.9, 40.7, 35.8, 20.6; LC-MS m/z [M+H]+ 
C25H28NO4+ calc. 406.2, found 406.2. 
(4R,4aR,7R,7aR,12bS)-9-((4-Methoxybenzyl)oxy)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-
4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol (7).  Compound 6 (229 mg, 0.57 mmol, 1 eq.), 
benzoic acid (104 mg, 0.85 mmol, 1.5 eq.) and triphenylphosphine (223 mg, 0.85 mmol, 1.5 eq.) 
were dissolved in anhydrous toluene (4 mL) and cooled to 0 oC. DIAD (167 µL, 0.85 mmol, 1.5 
eq.) in anhydrous toluene (0.5 mL) were then added dropwise over 2 min.  The reaction was then 
warmed to room temperature and allowed to stir for 4 h, after which the solvent was removed in 
vacuo.  The resulting residue was purified by flash column chromatography (59:40:1 
DCM/EtOAc/TEA) to give a white solid and oil mixture.  This residue was dissolved in a 1:1 
mixture of EtOH and 1 M aqueous KOH (6 mL) and heated to reflux for 20 min.  The reaction was 
then reduced in vacuo and 1 M citric acid (20 mL) was added to the residue.  The aqueous phase 
was then washed with EtOAc (3 × 20 mL), then neutralized with aqueous NH4OH (28%, 20 mL).  
The resulting solution was extracted with 3:1 CHCl3/iPrOH (3 × 20 mL).  The combined organic 
layers were backwashed with brine (20 mL), dried over Na2SO4 and the solvent removed in vacuo 
to give a white solid as the pure product (179 mg, 78%).  1H NMR (CDCl3) δ 7.36–7.31 (m, 1H), 
6.90–6.85 (m, 1H), 6.70 (d, J = 8.2 Hz, 1H), 6.50 (d, J = 8.2 Hz, 1H), 6.00–5.93 (m, 1H), 5.60 (dd, 
J = 9.8, 1.9 Hz, 1H), 5.05 (q, J = 11.4 Hz, 1H), 4.79 (s, 1H), 4.20 (d, J = 5.5 Hz, 1H), 3.79 (s, 1H), 
3.40 (dd, J = 5.6, 3.2 Hz, 1H), 3.17 (s, 1H), 3.03 (d, J = 18.7 Hz, 1H), 2.66 (dd, J = 12.2, 3.9 Hz, 
1H), 2.48 (s, 1H), 2.45–2.33 (m, 1H), 2.18 (td, J = 12.5, 4.9 Hz, 1H), 1.85 (dd, J = 12.7, 2.0 Hz, 
1H); 13C NMR (CDCl3) δ 159.5, 146.5, 141.3, 132.8, 131.4, 130.6, 129.6, 129.5, 127.2, 119.0, 
116.4, 113.9, 94.2, 71.7, 68.0, 59.3, 55.4, 47.2, 43.9, 42.9, 39.6, 35.5, 20.7; LC-MS m/z [M+H]+ 
C25H28NO4+ calc. 406.2, found 406.3. 
(4R,4aR,7S,7aR,12bS)-9-((4-Methoxybenzyl)oxy)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-
4,12-methanobenzofuro[3,2-e]isoquinolin-7-amine (8).  Compound 7 (174 mg, 0.43 mmol, 1 
eq.), phthalimide (79 mg, 0.64 mmol, 1.5 eq.) and triphenylphosphine (169 mg, 0.64 mmol, 1.5 eq.) 
were dissolved in anhydrous toluene (4 mL) and cooled to 0 oC.  DIAD (127 µL, 0.64 mmol, 1.5 
eq.) in anhydrous toluene (0.5 mL) was then added dropwise over 2 min.  The reaction was then 
warmed to room temperature and allowed to stir for 4 h, after which the solvent was removed in 
vacuo.  The resulting residue was purified by flash column chromatography (59:40:1 
DCM/EtOAc/TEA) to give a white solid and oil mixture.  To this residue, EtOH (10 mL) and 
N2H4.H2O (0.5 mL) were added and the mixture heated to reflux for 1 h.  After cooling, the 
resulting precipitate was filtered and washed with EtOH.  The filtrate was evaporated in vacuo, 
redissolved in CHCl3 and the resulting precipitate removed.  The filtrate was again evaporated in 
vacuo and the residue purified by flash column chromatography (89:10:1 CHCl3/MeOH/TEA) to 
give the product as a yellow oil (59 mg, 34%).  1H NMR (CDCl3) δ 7.35–7.30 (m, 1H), 6.89–6.80 
(m, 1H), 6.70 (d, J = 8.2 Hz, 1H), 6.55 (d, J = 8.2 Hz, 1H), 5.79–5.60 (m, 1H), 5.13–4.99 (m, 1H), 
4.94 (d, J = 2.3 Hz, 1H), 3.78 (s, 2H), 3.59 (d, J = 4.2 Hz, 1H), 3.03 (d, J = 18.7 Hz, 1H), 2.73 (d, J 
= 9.1 Hz, 1H), 2.55 (dd, J = 12.1, 3.6 Hz, 1H), 2.48–2.37 (m, 2H), 2.29 (td, J = 12.1, 3.7 Hz, 1H), 
2.03 (s, 1H), 1.99–1.93 (m, 1H), 1.83–1.77 (m, 1H); 13C NMR (CDCl3) δ 159.4, 145.0, 142.2, 
139.3, 130.1, 129.6, 129.5, 127.7, 123.9, 118.9, 116.3, 113.9, 87.4, 71.5, 56.2, 55.3, 49.2, 46.9, 
46.3, 43.2, 40.9, 35.5, 20.0; LC-MS m/z [M+H]+ C25H29N2O3+ calc. 405.5, found 405.2. 
6-O-Hexanoyl-3-O-(4-methoxybenzyl)morphine (9).  Compound 6 (68 mg, 0.17 mmol, 1 
eq.) and hexanoyl chloride (70.4 µL, 0.50 mmol, 3 eq.) were dissolved in pyridine (1 mL) and 
heated at 70oC in a sealed vessel for 19 h.  Water (2 mL) and MeOH (1 mL) were added and the 
resulting mixture evaporated.  MeCN (5 mL) was added and the mixture was again evaporated to 
give a yellow oil.  Saturated aqueous NaHCO3 (10 mL) was added and the resulting solution 
extracted with 3:1 CHCl3/iPrOH (3 × 10 mL).  The combined organic layers were backwashed with 
brine, dried over Na2SO4 and the solvent removed in vacuo to give a yellow oil.  Ether was added 
and the resulting precipitate filtered.  The filtrate was evaporated and purified by flash column 
chromatography (94:5:1 EtOAc/MeOH/TEA) to give the product as a yellow oil (67 mg, 80%).  1H 
NMR (CDCl3) δ 7.35–7.31 (m, 1H), 6.89–6.84 (m, 1H), 6.67 (d, J = 8.2 Hz, 1H), 6.49 (d, J = 8.2 
Hz, 1H), 5.67–5.61 (m, 1H), 5.46–5.39 (m, 1H), 5.19 (ddd, J = 8.1, 5.1, 2.9 Hz, 1H), 5.12 (dd, J = 
6.7, 0.8 Hz, 1H), 5.06 (s, 1H), 3.79 (s, 1H), 3.77 (dd, J = 3.6, 2.0 Hz, 1H), 3.40 (dd, J = 5.6, 3.2 Hz, 
1H), 3.02 (d, J = 18.7 Hz, 1H), 2.83 (s, 1H), 2.64 (dd, J = 12.0, 3.9 Hz, 1H), 2.47 (s, 2H), 2.42–2.28 
(m, 2H), 2.10 (td, J = 12.5, 4.9 Hz, 1H), 1.88 (dd, J = 12.7, 1.8 Hz, 1H), 1.69–1.58 (m, 1H), 1.35–
1.20 (m, 3H), 0.92–0.80 (m, 3H); 13C NMR (CDCl3) δ 173.4, 159.4, 147.6, 141.2, 130.9, 129.7, 
129.5, 129.2, 128.9, 119.4, 117.3, 113.8, 88.0, 71.8, 68.0, 59.3, 55.3, 43.0, 42.5, 40.4, 35.2, 34.1, 
31.4, 24.6, 22.4, 20.7, 14.02; LC-MS m/z [M+H]+ C31H37NO5+ calc. 504.3, found 504.3. 
N-((4R,4aR,7S,7aR,12bS)-9-((4-Methoxybenzyl)oxy)-3-methyl-2,3,4,4a,7,7a-hexahydro-
1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)hexanamide (10).  Compound 8 (65 mg, 0.16 
mmol, 1 eq.) and hexanoyl chloride (67 µL, 0.48 mmol, 3 eq.) were dissolved in pyridine (2 mL) 
and heated at 70 oC for 18 h.  After cooling, the solvent was removed in vacuo and the resulting 
residue was purified by flash column chromatography (94:5:1 EtOAc/MeOH/TEA) to give the 
product as a yellow oil (39 mg, 49%).  1H NMR (CDCl3) δ 7.37–7.30 (m, 2H), 6.89–6.84 (m, 2H), 
6.72 (d, J = 8.2 Hz, 1H), 6.59 (d, J = 8.2 Hz, 1H), 5.76 (ddd, J = 10.3, 3.5, 2.8 Hz, 1H), 5.60 (dd, J 
= 10.3, 1.1 Hz, 1H), 5.40 (d, J = 9.6 Hz, 1H), 5.09–5.00 (m, 2H), 4.94–4.92 (m, 1H), 4.23–4.14 (m, 
1H), 3.79 (s, 3H), 3.24 (dd, J = 5.8, 2.7 Hz, 1H), 2.99 (d, J = 18.8 Hz, 1H), 2.73 (dd, J = 18.8, 6.1 
Hz, 1H), 2.56–2.49 (m, 1H), 2.39 (s, 3H), 2.27 (td, J = 11.7, 4.5 Hz, 1H), 2.18–2.12 (m, 2H), 2.10 
(dd, J = 10.2, 2.8 Hz, 1H), 1.92–1.79 (m, 2H), 1.64–1.56 (m, 2H), 1.36–1.22 (m, 5H), 0.88 (t, J = 
7.0 Hz, 3H); 13C NMR (CDCl3) δ 173.1, 159.4, 144.9, 142.2, 134.7, 129.6, 129.5, 129.1, 128.2, 
126.2, 119.5, 116.5, 113.9, 86.6, 71.5, 56.7, 55.4, 47.7, 47.0, 44.3, 43.3, 41.1, 36.9, 35.6, 31.5, 25.5, 
22.5, 20.0, 14.1; LC-MS m/z [M+H]+ C31H39N2O4+ calc. 503.3, found 503.4. 
6-O-(3-Carboxypropanoyl)-3-O-(4-methoxybenzyl)morphine (11).  Compound 6 (41 mg, 
0.10 mmol, 1 eq.), succinic anhydride (15 mg, 0.15 mmol, 1.5 eq.), DMAP (19 mg, 0.15 mmol, 1.5 
eq.) and TEA (29 µL, 0.20 mmol, 2 eq.) were dissolved in dry MeCN (1 mL) under N2 and heated 
at 65 oC for 15.5 h.  The mixture was then evaporated and the residue purified via flash column 
chromatography (79:20:1 CHCl3/MeOH/NH4OH) to give the product as a white foam (40 mg, 
77%).  1H NMR (CDCl3) δ 9.98 (brs, 1H), 7.36–7.31 (m, 2H), 6.89–6.84 (m, 2H), 6.68 (d, J = 8.2 
Hz, 1H), 6.49 (d, J = 8.2 Hz, 1H), 5.62 (d, J = 10.0 Hz, 1H), 5.34–5.29 (m, 1H), 5.25–5.18 (m, J = 
13.8, 9.3, 4.7 Hz, 2H), 5.09 (s, 2H), 3.78 (s, 4H), 3.16 (s, 1H), 3.13–3.05 (m, 1H), 2.99 (d, J = 19.3 
Hz, 1H), 2.75 (ddd, J = 17.4, 10.0, 3.8 Hz, 1H), 2.63 (s, 3H), 2.62–2.53 (m, J = 10.5, 5.7 Hz, 3H), 
2.49–2.38 (m, 2H), 1.89 (d, J = 11.5 Hz, 1H); 13C NMR (CDCl3) δ 177.6, 172.9, 159.5, 147.8, 
141.6, 130.3, 129.7, 129.5, 129.5, 127.6, 124.7, 119.6, 118.3, 113.9, 87.9, 72.0, 67.8, 59.1, 55.4, 
46.6, 41.5, 41.1, 37.6, 33.1, 30.8, 30.0, 21.3; LC-MS m/z [M+H]+ C29H32NO7+ calc. 506.2, found 
506.2. 
4-(((4R,4aR,7S,7aR,12bS)-9-((4-Methoxybenzyl)oxy)-3-methyl-2,3,4,4a,7,7a-hexahydro-
1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-4-oxobutanoic acid (12).  Compound 
8 (71 mg, 0.18 mmol, 1 eq.), succinic anhydride (26 mg, 0.26 mmol, 1.5 eq.), DMAP (32 mg, 0.26 
mmol, 1.5 eq.) and TEA (49 µL, 0.35 mmol, 2 eq.) were dissolved in MeCN (3 mL) and heated to 
70 oC for 18 h.  The solvent was then removed in vacuo and the resulting solid was triturated with 
EtOAc.  The resulting material was suspended in hot EtOH and the resulting precipitate filtered to 
give the product as a white solid (25 mg, 28%).  1H NMR (DMSO-d6) δ 7.35–7.29 (m, 2H), 6.95–
6.89 (m, 2H), 6.78 (d, J = 8.2 Hz, 1H), 6.61 (d, J = 8.2 Hz, 1H), 5.69–5.63 (m, 1H), 5.56 (dd, J = 
10.4, 1.2 Hz, 1H), 5.01–4.96 (m, 3H), 3.74 (s, 3H), 3.16 (s, 1H), 3.13 (dd, J = 5.7, 2.6 Hz, 1H), 2.87 
(d, J = 18.7 Hz, 1H), 2.46 (d, J = 7.2 Hz, 1H), 2.44–2.39 (m, 3H), 2.34–2.30 (m, 1H), 2.28 (s, 3H), 
2.15 (dd, J = 10.5, 2.7 Hz, 1H), 2.13–2.05 (m, 2H), 1.83 (td, J = 12.3, 4.7 Hz, 1H), 1.60 (d, J = 11.1 
Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 174.1, 171.3, 159.0, 147.4, 144.4, 141.6, 136.0, 129.7, 
129.4, 129.2, 128.0, 125.0, 118.9, 115.6, 113.7, 106.8, 86.2, 70.2, 55.3, 55.1, 46.2, 43.4, 42.8, 38.8, 
34.9, 30.0, 29.7, 29.2, 19.6; LC-MS m/z [M+H]+ C29H33N2O6+ calc. 505.2, found 505.3. 
3-O-(4-Methoxybenzyl)-6-O-(4-Methylamino-4-oxobutanoyl)morphine (13).  Compound 
11 (40 mg, 0.079 mmol, 1 eq.), EDC.HCl (23 mg, 0.12 mmol, 1.5 eq.), anhydrous HOBt (16 mg, 
0.12 mmol, 1.5 eq.) and TEA (22 µL, 0.16 mmol, 2 eq.) were dissolved in MeCN (2 mL) and stirred 
at room temperature for 1 h.  Methylamine (2 M solution in THF, 79.2 µL, 0.1584 mmol, 2 eq.) was 
then added and stirred for an additional 2 h.  The reaction mixture was then evaporated and purified 
by flash column chromatography (0.5 – 6% MeOH in CHCl3 with 1% TEA) to give the product as a 
slightly yellow oil (26 mg, 63%).  1H NMR (CDCl3) δ 7.36–7.28 (m, 2H), 6.90–6.84 (m, 2H), 6.71 
(d, J = 8.2 Hz, 1H), 6.52 (d, J = 8.2 Hz, 1H), 5.80 (d, J = 4.0 Hz, 1H), 5.63–5.57 (m, 1H), 5.47–5.38 
(m, 1H), 5.17 (ddd, J = 8.9, 5.0, 3.0 Hz, 1H), 5.09 (dd, J = 6.9, 0.8 Hz, 1H), 5.04–4.97 (m, 2H), 
3.79 (s, 3H), 3.37 (dd, J = 5.7, 3.2 Hz, 1H), 3.05 (dd, J = 8.8, 5.9 Hz, 1H), 3.02–2.98 (m, 1H), 2.78 
(s, 1H), 2.73–2.67 (m, 2H), 2.60 (d, J = 4.8 Hz, 3H), 2.45 (s, 3H), 2.43–2.27 (m, 4H), 2.07 (td, J = 
12.4, 5.0 Hz, 1H), 1.86 (dd, J = 12.7, 1.6 Hz, 1H), 1.37 (t, J = 7.3 Hz, 1H); 13C NMR (CDCl3) δ 
172.1, 172.1, 159.7, 147.2, 141.2, 130.9, 129.7, 129.4, 129.1, 128.5, 127.7, 119.5, 116.0, 114.0, 
87.9, 71.7, 68.0, 59.3, 55.4, 46.8, 45.9, 43.1, 42.5, 40.4, 35.3, 31.5, 30.4, 26.4, 20.5, 9.0; LC-MS 
m/z [M+H]+ C30H35N2O6+ calc. 519.3, found 519.2. 
N1-((4R,4aR,7S,7aR,12bS)-9-((4-methoxybenzyl)oxy)-3-methyl-2,3,4,4a,7,7a-hexahydro-
1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)-N4-methylsuccinamide (14).  Compound 12 
(24 mg, 0.48 mmol, 1 eq.), EDC.HCl (14 mg, 0.072 mmol, 1.5 eq.), anhydrous HOBt (10 mg, 0.072 
mmol, 1.5 eq.) and TEA (13 µL, 0.096 mmol, 2 eq.) were dissolved in dry DMF (1 mL) and stirred 
at room temperature for 1 h.  Methylamine (2 M in THF, 48 µL, 0.096 mmol, 2 eq.) was then added 
and the reaction allowed to stir for 19 h.  Additional EDC.HCl (18 mg, 0.094 mmol, 2 eq.) and 
HOBt (11 mg, 0.084 mmol, 1.7 eq.) were added, and following 30 min of stirring, further 
methylamine (2 M in THF, 48 µL, 0.096 mmol, 2 eq.) were added.  The reaction was then allowed 
to stir at room temperature for a further 24 h and the solvent removed in vacuo.  The resulting 
brown oil was purified by PLC (89:10:1 CHCl3/MeOH/TEA) to give the product as a white solid 
(21 mg, 84%).  1H NMR (CDCl3) δ 7.35–7.30 (m, 2H), 6.89–6.83 (m, 2H), 6.71 (d, J = 8.2 Hz, 1H), 
6.58 (d, J = 8.2 Hz, 1H), 6.30 (d, J = 9.5 Hz, 1H), 6.06 (d, J = 4.2 Hz, 1H), 5.75 (ddd, J = 10.3, 3.5, 
2.9 Hz, 1H), 5.59 (dd, J = 10.3, 1.1 Hz, 1H), 5.08–5.00 (m, 2H), 4.95–4.91 (m, 1H), 4.16–4.07 (m, 
1H), 3.79 (s, 3H), 3.23 (dd, J = 5.9, 2.7 Hz, 1H), 2.97 (d, J = 18.7 Hz, 1H), 2.76 (d, J = 4.8 Hz, 3H), 
2.65 (d, J = 6.1 Hz, 1H), 2.55–2.44 (m, 5H), 2.39 (s, 3H), 2.27 (td, J = 12.0, 3.7 Hz, 1H), 2.17 (dd, J 
= 10.3, 2.8 Hz, 1H), 1.88 (td, J = 12.2, 4.8 Hz, 1H), 1.84–1.76 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 172.7, 172.4, 159.4, 145.0, 142.3, 134.6, 129.6, 129.5, 129.2, 128.1, 126.1, 119.4, 116.5, 
113.9, 86.7, 71.6, 56.5, 55.4, 47.0, 47.0, 46.2, 44.6, 43.2, 41.0, 35.5, 32.0, 31.7, 26.5, 20.1, 10.7; 
LC-MS m/z [M+H]+ C30H36N3O5+ calc. 518.3, found 518.4. 
6-O-Carboxymethylmorphine (15).  Compound 6 (93 mg, 0.23 mmol, 1 eq.) was dissolved 
in dry THF (3 mL) and cooled to 0oC under an N2 atmosphere.  To this solution, a suspension of 
prewashed NaH (60%, 37 mg, 0.92 mmol, 4 eq.) in THF (1 mL) was added dropwise.  The solution 
was then allowed to warm to room temperature and stir for 15 min.  A solution of tert-butyl 
bromoacetate in THF (1 mL) was then added dropwise and allowed to stir at room temperature for 1 
h.  The reaction was then quenched with saturated NH4Cl (2 mL), then MeCN (2 mL) was added.  
The resulting solution was reduced in vacuo and saturated NaHCO3 (20 mL) was added and 
extracted with CHCl3 (3 × 20 mL).  The combined organic phases were backwashed with brine (20 
mL), dried over Na2SO4, and the solvent removed in vacuo to give a brown oil.  The crude oil was 
dissolved in DCM (3 mL) under an N2 atmosphere.  Triethylsilane (1.1 mL, 6.9 mmol, 30 eq.), TFA 
(1 mL) were then added and the reaction vessel purged with N2.  The reaction was allowed to stir 
for 1 h, then reduced in vacuo.  The resulting oil was purified by prep-HPLC to give the product as 
a solid white TFA salt (61 mg, 58%).  1H NMR (DMSO-d6) δ 10.13 (s, 1H), 9.16 (s, 1H), 6.56 (d, J 
= 8.1 Hz, 1H), 6.46 (d, J = 8.1 Hz, 1H), 5.76 (d, J = 9.9 Hz, 2H), 5.35 (d, J = 9.7 Hz, 2H), 5.14–
5.04 (m, 2H), 4.19 (s, 3H), 4.12 (dd, J = 16.4, 3.9 Hz, 3H), 3.30 (d, J = 12.7 Hz, 2H), 3.20 (d, J = 
19.8 Hz, 1H), 3.02 (d, J = 26.9 Hz, 2H), 2.89 (s, 3H), 2.82 (s, 2H), 2.74 (dd, J = 19.1, 7.3 Hz, 1H), 
2.19 (td, J = 13.6, 4.1 Hz, 1H), 1.95 (d, J = 12.5 Hz, 1H); 13C NMR (DMSO-d6) δ 171.6, 146.2, 
139.3, 131.9, 128.8, 125.9, 121.9, 119.3, 117.2, 87.1, 73.4, 65.4, 59.6, 46.5, 41.4, 40.5, 38.2, 32.8, 
20.8; LC-MS m/z [M+H]+ C19H22NO5+ calc. 344.2, found 344.2. 
3-O-PMB-(6-O-(4-((2-tert-butoxycarbonyl)amino)ethyl)amino-4-oxobutanoyl)morphine 
(16).  Compound 11 (96.5 mg, 0.19 mmol, 1 eq.), HCTU (95 mg, 0.23 mmol, 1.2 eq.) and TEA (54 
µL, 0.38 mmol, 2 eq.) were dissolved in dry DMF (1.5 mL) under an N2 atmosphere and was 
allowed to stir at room temperature for 30 min.  tert-Butyl (4-aminoethyl)carbamate (37 mg, 0.23 
mmol, 1.2 eq.) was then added as a solution in dry DMF (0.5 mL) and allowed to stir at room 
temperature for 19 h.  EtOAc (20 mL) was then added and the resulting solution was washed with 
half-saturated NaHCO3 (3 × 10 mL), saturated NaHCO3 (20 mL), half saturated brine (2 × 10 mL) 
and brine (20 mL).  The organic phase was then dried over Na2SO4 and the solvent removed in 
vacuo.  The resulting residue was purified by flash column chromatography (98:1:1 
CHCl3/MeOH/TEA) to give the product as a clear glass (102 mg, 83%).  1H NMR (CDCl3) δ 7.30 
(d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.2 Hz, 1H), 6.54 (d, J = 8.2 Hz, 1H), 6.31 
(t, J = 5.5 Hz, 1H), 5.59 (d, J = 10.1 Hz, 1H), 5.47–5.39 (m, 1H), 5.30 (s, 1H), 5.18–5.08 (m, 2H), 
4.98 (s, 2H), 3.77 (s, 3H), 3.33 (dd, J = 5.5, 3.3 Hz, 1H), 3.30–3.23 (m, 1H), 3.11–2.97 (m, 3H), 
2.96–2.87 (m, 1H), 2.73 (s, 1H), 2.70–2.61 (m, 2H), 2.57 (dd, J = 12.2, 3.8 Hz, 1H), 2.41 (s, 3H), 
2.40–2.34 (m, 1H), 2.29 (ddd, J = 18.1, 9.0, 4.5 Hz, 3H), 2.07–1.97 (m, 1H), 1.84 (d, J = 11.1 Hz, 
1H), 1.33 (s, 9H); 13C NMR (CDCl3) δ 171.9, 171.8, 159.8, 156.4, 146.5, 141.2, 130.8, 129.9, 
129.5, 128.6, 128.4, 127.7, 119.6, 114.8, 114.0, 87.7, 71.3, 67.7, 59.2, 55.4, 46.8, 43.1, 42.4, 40.6, 
40.4, 39.9, 35.2, 31.8, 30.5, 28.4, 20.3; LC-MS m/z [M+H]+ C36H46N3O8+ calc. 648.3, found 648.4. 
6-O-(4-((2-Aminoethyl)amino)-4-oxobutanoyl)morphine (17).  Compound 16 (102 mg, 
0.16 mmol, 1 eq.) was deprotected using general deprotection procedure A.  The resulting residue 
was purified by prep-HPLC to give the product as a solid white mono-TFA salt (43 mg, 51%).  1H 
NMR (DMSO-d6) δ 10.01 (s, 1H), 9.22 (s, 1H), 8.10 (t, J = 5.7 Hz, 1H), 7.75 (s, 3H), 6.59 (d, J = 
8.1 Hz, 1H), 6.51 (dd, J = 8.0, 4.2 Hz, 1H), 5.65 (d, J = 10.0 Hz, 1H), 5.52–5.39 (m, 1H), 5.25–5.14 
(m, 1H), 5.09–4.98 (m, 1H), 4.13 (s, 1H), 3.27 (dd, J = 12.2, 6.2 Hz, 2H), 3.19 (d, J = 19.8 Hz, 1H), 
3.06 (d, J = 4.7 Hz, 1H), 2.97 (s, 1H), 2.89 (s, 2H), 2.84 (dd, J = 12.1, 6.0 Hz, 2H), 2.71 (dd, J = 
20.0, 6.7 Hz, 1H), 2.65–2.59 (m, 2H), 2.45 (t, J = 6.8 Hz, 2H), 2.20 (dd, J = 13.4, 9.1 Hz, 1H), 1.84 




dien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium-5-sulfonate (18).  Compound 17 (7.1 mg, 0.013 mmol, 
2 eq.), Sulfo-Cy5 NHS ester (Lumiprobe, 5 mg, 0.0066 mmol, 1 eq.) and TEA (2.8 µL, 0.020 
mmol, 3 eq.) was dissolved in dry DMF (150 µL) under an N2 atmosphere and allowed to stir at 
room temperature for 7 h.  HCTU (2.7 mg, 0.0066 mmol, 1 eq.) was then added and the reaction 
stirred for an additional 16 h.  Water (20 mL) and MeCN (1 mL) were then added and the solvent 
removed by freeze-drying.  The resulting residue was purified by reverse phase chromatography (5 
– 30% buffer B in buffer A, 1% jump per column volume).  Clean fractions were collected and 
freeze-dried to give the product as a dark blue solid TFA salt (2.6 mg, 33%).  1H NMR (DMSO-d6) 
δ 9.82 (s, 1H), 9.20 (s, 1H), 8.35 (t, J = 13.1 Hz, 1H), 7.91 (s, 1H), 7.81 (s, 2H), 7.77 (s, 1H), 7.64 
(dd, J = 7.6, 3.9 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 6.62–6.44 (m, 5H), 6.28 (dd, J = 18.3, 13.9 Hz, 
2H), 5.59 (d, J = 9.9 Hz, 1H), 5.41 (d, J = 9.7 Hz, 1H), 5.12–4.93 (m, 2H), 4.08 (s, 4H), 3.59 (s, 
2H), 3.16–3.02 (m, 7H), 2.89 (s, 4H), 2.60–2.54 (m, 3H), 2.39 (t, J = 6.6 Hz, 3H), 2.03 (t, J = 7.1 
Hz, 2H), 1.68 (s, 12H), 1.58–1.48 (m, 2H), 1.29 (ddd, J = 17.8, 13.8, 8.6 Hz, 5H), 1.17 (t, J = 7.3 
Hz, 2H); ESI-TOF HRMS m/z [M+H]+ C55H66N5O12S2+ calc. 1052.4144, found 1052.4119, 
[M+2H]2+ C55H67N5O12S2+ calc. 526.7108, found 526.7113. 
6-O-((4-((tert-Butoxycarbonyl)amino)butyl)carbamoyl)morphine (19).  Compound 15 
(130 mg, 0.28 mmol, 1 eq.), anhydrous HOBt (42 mg, 0.31 mmol, 1.1 eq.), EDC.HCl (60 mg, 0.31 
mmol, 1.1 eq.) and TEA (119 µL, 85 mmol, 3 eq.) were dissolved in DMF (2 mL) under an N2 
atmosphere and allowed to stir at room temperature for 1 h.  tert-Butyl (4-aminobutyl)carbamate 
(64 mg, 0.34 mmol, 1.2 eq.) was then added as a solution in dry DMF (1 mL) and the reaction 
stirred at room temperature for 17 h.  The solvent was then removed in vacuo and the residue 
purified by reverse phase chromatography (6–35% buffer B in buffer A, 1% jump per column 
volume).  Clean fractions were collected and freeze dried to give the product as a light-orange solid 
TFA salt (65 mg, 36%).  1H NMR (MeOD) δ 6.65 (dd, J = 8.1, 1.4 Hz, 1H), 6.58 (d, J = 8.1 Hz, 
1H), 5.92–5.83 (m, 1H), 5.42 (d, J = 9.9 Hz, 1H), 5.19–5.12 (m, 1H), 4.91 (s, 9H), 4.28–4.10 (m, 
4H), 3.39 (dd, J = 13.3, 3.7 Hz, 1H), 3.34 (d, J = 6.5 Hz, 1H), 3.26 (d, J = 7.3 Hz, 1H), 3.20 (d, J = 
20.2 Hz, 1H), 3.12–2.94 (m, 7H), 2.87 (dd, J = 19.8, 6.8 Hz, 1H), 2.34 (td, J = 13.6, 5.0 Hz, 1H), 
2.12 (d, J = 13.9 Hz, 1H), 1.75–1.62 (m, 3H), 1.60–1.47 (m, 2H), 1.42 (s, 3H); 13C NMR (MeOD) δ 
172.6, 147.4, 132.9, 129.9, 126.6, 121.2, 118.7, 89.0, 75.3, 69.8, 69.7, 62.3, 42.9, 41.7, 40.3, 40.0, 
39.7, 39.1, 34.3, 28.8, 28.3, 27.7, 27.4, 25.8, 22.2; LC-MS m/z [M+H]+ C28H40N3O6+ calc. 514.3, 
found 514.3. 
6-O-((4-Aminobutyl)carbamoyl)morphine (20).  Compound 19 (65 mg, 0.10 mmol, 1 eq.) 
was dissolved in CHCl3 (1 mL) and TFA (0.5 mL) and the resulting solution allowed to stir for 1 h.  
The solvent was then removed in vacuo, the resulting residue dissolved in buffer A and freeze-dried 
to give the product as a brown oil TFA salt (60 mg, quantitative).   1H NMR (MeOD) δ 6.65 (d, J = 
8.1 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 5.86 (d, J = 10.0 Hz, 1H), 5.41 (d, J = 9.8 Hz, 1H), 5.15 (d, J 
= 5.7 Hz, 1H), 4.28–4.10 (m, 4H), 3.38 (dd, J = 13.2, 3.8 Hz, 1H), 3.33 (d, J = 6.7 Hz, 1H), 3.27 (d, 
J = 20.0 Hz, 1H), 3.18 (d, J = 12.0 Hz, 1H), 3.07 (dd, J = 13.3, 3.5 Hz, 1H), 3.04–2.93 (m, 6H), 
2.87 (dd, J = 19.9, 6.7 Hz, 1H), 2.36 (td, J = 13.6, 4.6 Hz, 1H), 2.09 (d, J = 12.0 Hz, 1H), 1.77–1.58 
(m, 4H); 13C NMR (101 MHz, MeOD) δ 172.5, 147.4, 141.0, 132.8, 129.9, 126.7, 123.2, 121.2, 
118.7, 89.0, 75.4, 69.7, 62.2, 42.9, 41.7, 40.3, 39.8, 39.1, 34.2, 27.3, 26.8, 25.8, 22.2; LC-MS m/z 




dien-1-yl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate (21).  Sulfo-Cy5 TFA salt (6.0 mg, 7.8 µmol, 
1 eq.), HCTU (3.9 mg, 9.3 µmol, 1.2 eq.), TEA (10 µL) were dissolved in DMF (600 µL) under an 
N2 atmosphere and stirred at room temperature for 1 h.  Compound 20 (8.2 mg, 16 µmol, 2 eq.) was 
then added as a solution in DMF (200 µL) and allowed to stir at room temperature for 18 h.  Buffer 
A was added and the resulting solution freeze-dried.  The residue was purified by reverse phase 
chromatography (5–30% buffer B in buffer A, 1% jump per column volume).  Clean fractions were 
collected and freeze-dried to give the product as a dark blue solid TFA salt (3.6 mg, 40%).  1H 
NMR (DMSO-d6) δ 10.22 (s, 1H), 9.19 (s, 1H), 8.35 (t, J = 12.6 Hz, 2H), 7.82 (s, 2H), 7.78–7.71 
(m, 2H), 7.68–7.61 (m, 2H), 7.34–7.30 (m, 2H), 7.18 (s, 1H), 7.05 (s, 1H), 6.59–6.55 (m, 2H), 6.46 
(d, J = 8.1 Hz, 1H), 6.30 (d, J = 14.0 Hz, 1H), 5.77 (dd, J = 10.2, 2.2 Hz, 1H), 5.28 (d, J = 10.0 Hz, 
1H), 5.07 (d, J = 5.9 Hz, 1H), 4.15–3.93 (m, 10H), 3.19 (d, J = 19.3 Hz, 1H), 3.14–3.04 (m, 5H), 
3.02–2.96 (m, 3H), 2.89 (s, 3H), 2.82 (s, 1H), 2.75–2.66 (m, 1H), 2.23–2.13 (m, 1H), 2.02 (t, J = 
6.9 Hz, 2H), 1.95–1.89 (m, 1H), 1.58–1.48 (m, 3H), 1.43–1.29 (m, 8H), 1.25 (t, J = 7.3 Hz, 6H), 
1.17 (t, J = 7.3 Hz, 2H); ESI-TOF HRMS m/z [M+H]+ C56H70N5O11S2+ calc. 1052.4508, found 
1052.4545, [M+Na]+ C56H69N5O11S2Na+  calc. 1074.4327, found 1074.4338. 
Pharmacology.  cAMP BRET CAMYEL assay.  HEK293 cells were transfected with 2 µg 
hMOR pEF5/FRT construct cDNA and 3 µg CAMYEL sensor cDNA.  The cDNA was mixed with 
30 µg polyethylenimine and made up to 250 µL with 0.15 M NaCl, then allowed to incubate for 15–
20 min at room temperature.  This mixture was then added to the cells dropwise and gently mixed. 
The cells were then incubated for 24 h in PTM, after which they were resuspended in 15 mL PTM 
and replated onto white poly-D-lysine coated plates at 100 µL per well and maintained for 24 h.  
The media was then aspirated and the cells washed once with 100 µL/well HBSS at 37 oC.  HBSS 
(70 µL/well) was then added back and the cells incubated for 30 min at 37 oC in the absence of 
CO2.  Coelenterazine H (10 µL, 5 µM final) was added and the cells incubated in the dark for 10 
min at 37 oC.  The drugs (10 µL) were then added at the desired concentration, followed 
immediately by forskolin (10 µL, 30 µM final), then incubated for 5 min inside a LUMIstar Omega 
plate reader set at 37 oC.  Luminescence for RLuc8 (480 nm) and fluorescence for YFP (530 nm) 
were then measured.  Baseline and vehicle control values were subtracted and the BRET signal was 
normalized as a percentage of forskolin response. 
Confocal Microscopy.  HEK293 cells stably expressing N-terminal SNAP-hMOR were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal calf 
serum (FCS) and 1 mg/mL G418.  Cells were grown in poly-D-lysine–coated 8-well Labtek 
borosilicate chambered-cover glasses (Nalgene Nunc International, Fisher Scientific).  On the day 
of experimentation, SNAP tag labelling was performed by incubating cells in 500 nM BG-488 in 
fresh cell culture media for 30 min at 37 °C.  Cells were washed in pre-warmed HEPES-buffered 
saline solution (HBS) containing 4.5 mM D-glucose and incubated for 30 min at 37 °C in the 
presence or absence of 1 µM naloxone prior to addition and incubation with the relevant 
concentration of 21 for 30 min at 37 °C. Where the concentration of 21 was 10 µM, the cells were 
washed with HBS prior to imaging.  Confocal images were captured using a Zeiss LSM710 laser 
scanning microscope using a Plan-Apochromat 63 × 1.3NA oil-immersion objective lens (1024 × 
1024 pixels, averaging at four frames).  The 633 nm HeNe and 488 nm argon lasers were used to 
excite sulfo-Cy5 and BG-488 respectively.  Emission was captured at 638 – 759 nm and 493 – 628 
nm respectively.  Confocal settings for laser power, offset and gain were kept constant throughout 
acquisition.  Images were processed in Zeiss Zen 2011, with any linear adjustments made equally 
cross all images within a dataset. 
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